Analytical Data
-
Gene name
INSM1
- Application
-
Alternative Names
IA1; Zinc finger protein IA-1
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q01101
-
Expression Region
Ser13~Phe173
-
Molecular Weight
46kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
INSM1 (Insulinoma-associated Protein 1) is a transcription factor that plays a critical role in neuroendocrine differentiation and is implicated in the development of certain tumors, particularly neuroendocrine tumors and pancreatic neuroendocrine neoplasms. It is increasingly recognized as a potential biomarker for diagnosing and prognosticating various cancers, particularly those of neuroendocrine origin. Research into the recombinant form of INSM1 has gained traction due to its significance in understanding tumor biology and its potential applications in targeted therapies.
The expression levels of INSM1 in tumor tissues compared to normal tissues have provided insights into its role in tumorigenesis, making it a candidate for further study. Additionally, the characterization of INSM1 recombinant protein allows for exploration of its functional mechanisms, interactions with other proteins, and its role in the regulatory networks that govern neuroendocrine differentiation. The ability to produce INSM1 in recombinant form facilitates detailed structural and functional assays, crucial for the development of therapeutic agents that could inhibit its aberrant expression or activity in tumors. Furthermore, elucidating the pathway through which INSM1 operates could lead to novel interventions in cancer treatment, underscoring the urgent need for extensive research in this area. The overall landscape of INSM1 research reflects its growing importance in cancer biology, with the potential to contribute significantly to the fields of oncology and personalized medicine.
